1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Ischemic Cerebral Stroke - Pipeline Review, H2 2014

Ischemic Cerebral Stroke - Pipeline Review, H2 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 37 pages

Ischemic Cerebral Stroke - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Ischemic Cerebral Stroke - Pipeline Review, H2 2014’, provides an overview of the Ischemic Cerebral Stroke’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemic Cerebral Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Cerebral Stroke and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ischemic Cerebral Stroke
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ischemic Cerebral Stroke and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ischemic Cerebral Stroke products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ischemic Cerebral Stroke pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ischemic Cerebral Stroke
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ischemic Cerebral Stroke pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Ischemic Cerebral Stroke - Pipeline Review, H2 2014
Table of Contents

Introduction 5
Global Markets Direct Report Coverage 5
Ischemic Cerebral Stroke Overview 6
Therapeutics Development 7
Pipeline Products for Ischemic Cerebral Stroke - Overview 7
Pipeline Products for Ischemic Cerebral Stroke - Comparative Analysis 8
Ischemic Cerebral Stroke - Therapeutics under Development by Companies 9
Ischemic Cerebral Stroke - Therapeutics under Investigation by Universities/Institutes 10
Ischemic Cerebral Stroke - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Ischemic Cerebral Stroke - Products under Development by Companies 13
Ischemic Cerebral Stroke - Products under Investigation by Universities/Institutes 14
Ischemic Cerebral Stroke - Companies Involved in Therapeutics Development 15
Neurotec Pharma SL 15
Stempeutics Research Private Limited 16
Ischemic Cerebral Stroke - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
BSc-2118 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
NTKC-005 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Recombinant Peptide for Ischemic Cerebral Stroke - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Recombinant Protein for Ischemic Cerebral Stroke - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Stempeucel - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Ischemic Cerebral Stroke - Recent Pipeline Updates 33
Ischemic Cerebral Stroke - Discontinued Products 34
Ischemic Cerebral Stroke - Product Development Milestones 35
Featured News and Press Releases 35
Oct 01, 2014: Zocere's Stroke Drug to Be Featured at BIO Investor Forum 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables

Number of Products under Development for Ischemic Cerebral Stroke, H2 2014 7
Number of Products under Development for Ischemic Cerebral Stroke - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Ischemic Cerebral Stroke - Pipeline by Neurotec Pharma SL, H2 2014 15
Ischemic Cerebral Stroke - Pipeline by Stempeutics Research Private Limited, H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Ischemic Cerebral Stroke Therapeutics - Recent Pipeline Updates, H2 2014 33
Ischemic Cerebral Stroke - Discontinued Products, H2 2014 34

List of Figures

Number of Products under Development for Ischemic Cerebral Stroke, H2 2014 7
Number of Products under Development for Ischemic Cerebral Stroke - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 12
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Top 10 Targets, H2 2014 18
Number of Products by Stage and Top 10 Targets, H2 2014 19
Number of Products by Top 10 Mechanism of Actions, H2 2014 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 21
Number of Products by Top 10 Routes of Administration, H2 2014 22
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 23
Number of Products by Top 10 Molecule Types, H2 2014 24
Number of Products by Stage and Top 10 Molecule Types, H2 2014 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
North America And Europe Stroke Diagnostics Market Analysis By Technology, By Region And Segment Forecasts To 2024

North America And Europe Stroke Diagnostics Market Analysis By Technology, By Region And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The North America and Europe stroke diagnostics market is expected to reach USD 1.4 million by 2024, according to a new report by Grand View Research Inc. The stroke diagnostics market is anticipated to ...

Acute ischemic stroke (AIS)- Market Insights, Epidemiology and Market Forecast-2023

Acute ischemic stroke (AIS)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute ischemic stroke (AIS) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Global In Vitro Diagnostics 2010-2016: Deal trends, players, financials and forecasts

Global In Vitro Diagnostics 2010-2016: Deal trends, players, financials and forecasts

  • $ 2995
  • Industry report
  • November 2016
  • by Currentpartnering

The Global In Vitro Diagnostics Partnering 2010-2016 report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals. These deals tend to be ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.